Quantitative Prediction of Transporter- and Enzyme-Mediated Clinical Drug-Drug Interactions of Organic Anion-Transporting Polypeptide 1B1 Substrates Using a Mechanistic Net-Effect Model
暂无分享,去创建一个
Jian Lin | M. Varma | E. Kimoto | Jian Lin | Y. Bi | Yi-an Bi | Emi Kimoto | Manthena V. Varma | Emi Kimoto
[1] Jian Lin,et al. Mechanism-Based Pharmacokinetic Modeling to Evaluate Transporter-Enzyme Interplay in Drug Interactions and Pharmacogenetics of Glyburide , 2014, The AAPS Journal.
[2] Tristan S. Maurer,et al. A Combined Model for Predicting CYP3A4 Clinical Net Drug-Drug Interaction Based on CYP3A4 Inhibition, Inactivation, and Induction Determined in Vitro , 2008, Drug Metabolism and Disposition.
[3] A Rostami-Hodjegan,et al. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. , 2010, Current drug metabolism.
[4] P. Neuvonen,et al. Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake , 2011, Pharmacological Reviews.
[5] J. Houston,et al. The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions , 2006, Journal of Pharmacology and Experimental Therapeutics.
[6] L J Lesko,et al. Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling , 2007, Clinical pharmacology and therapeutics.
[7] R. Kim,et al. Polymorphisms in OATP-C , 2001, The Journal of Biological Chemistry.
[8] B. Feng,et al. Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions , 2012, Pharmaceutical Research.
[9] P. Bullock. Prediction of Pharmacokinetics and Drug Safety in Humans , 2010 .
[10] Tudor I. Oprea,et al. BDDCS Applied to Over 900 Drugs , 2011, The AAPS Journal.
[11] K. Maeda,et al. Transporter‐Mediated Drug–Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies , 2012, Clinical pharmacology and therapeutics.
[12] Hugh A. Barton,et al. Mechanistic Pharmacokinetic Modeling for the Prediction of Transporter-Mediated Disposition in Humans from Sandwich Culture Human Hepatocyte Data , 2012, Drug Metabolism and Disposition.
[13] H. Barton,et al. Prediction of Pharmacokinetics and Drug–Drug Interactions When Hepatic Transporters are Involved , 2014, Clinical Pharmacokinetics.
[14] H. Kusuhara,et al. The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. , 2003, Drug metabolism and pharmacokinetics.
[15] Mary F Paine,et al. THE HUMAN INTESTINAL CYTOCHROME P450 “PIE” , 2006, Drug Metabolism and Disposition.
[16] Amy Roe,et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[17] Guideline on the Investigation of Drug Interactions , 2010 .
[18] M Jamei,et al. ITC Recommendations for Transporter Kinetic Parameter Estimation and Translational Modeling of Transport‐Mediated PK and DDIs in Humans , 2013, Clinical pharmacology and therapeutics.
[19] Hugh A Barton,et al. Model-based approaches to predict drug–drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond , 2013, Expert opinion on drug metabolism & toxicology.
[20] L. Tremaine,et al. Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability – considerations for drug development , 2012, Expert opinion on drug metabolism & toxicology.
[21] C. Gui,et al. Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. , 2008, European journal of pharmacology.
[22] Yuichi Sugiyama,et al. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. , 2006, Pharmacology & therapeutics.
[23] Y. Sugiyama,et al. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs , 2009, Expert opinion on drug metabolism & toxicology.
[24] M. Rowland,et al. Hepatic clearance of drugs. II. Experimental evidence for acceptance of the “well-stirred” model over the “parallel tube” model using lidocaine in the perfused rat liverin situ preparation , 1977, Journal of Pharmacokinetics and Biopharmaceutics.
[25] Prajakti A Kothare,et al. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin. , 2014, British journal of clinical pharmacology.
[26] A. Treiber,et al. Inhibitory and Inductive Effects of Rifampin on the Pharmacokinetics of Bosentan in Healthy Subjects , 2007, Clinical pharmacology and therapeutics.
[27] Hugh A Barton,et al. The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance , 2012, Xenobiotica; the fate of foreign compounds in biological systems.
[28] Jianghong Fan,et al. PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism. , 2010, Current drug metabolism.
[29] Y. Lai,et al. Quantitative assessment of the contribution of sodium‐dependent taurocholate co‐transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin , 2013, Biopharmaceutics & drug disposition.
[30] A. Mazzu,et al. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin , 2000, Clinical pharmacology and therapeutics.
[31] U. Hofmann,et al. Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17 , 2005, Pharmacogenetics and genomics.
[32] T. Goosen,et al. Mechanistic Modeling to Predict the Transporter- and Enzyme-Mediated Drug-Drug Interactions of Repaglinide , 2013, Pharmaceutical Research.
[33] L. Zhang,et al. Evaluation of Various Static and Dynamic Modeling Methods to Predict Clinical CYP3A Induction Using In Vitro CYP3A4 mRNA Induction Data , 2014, Clinical pharmacology and therapeutics.
[34] Shu-Feng Zhou,et al. Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. , 2009, Current drug metabolism.
[35] Aleksandra Galetin,et al. Use of Mechanistic Modeling to Assess Interindividual Variability and Interspecies Differences in Active Uptake in Human and Rat Hepatocytes , 2012, Drug Metabolism and Disposition.
[36] R. Collins,et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.
[37] Yuichi Sugiyama,et al. Polymorphisms of OATP‐C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics , 2003, Clinical pharmacology and therapeutics.
[38] Gian Camenisch,et al. Predicting human hepatic clearance from in vitro drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug–drug interactions , 2012, Biopharmaceutics & drug disposition.
[39] K. Pang,et al. THE ROLES OF TRANSPORTERS AND ENZYMES IN HEPATIC DRUG PROCESSING , 2005, Drug Metabolism and Disposition.
[40] Aleksandra Galetin,et al. Multiple Inhibition Mechanisms and Prediction of Drug–Drug Interactions: Status of Metabolism and Transporter Models as Exemplified by Gemfibrozil–Drug Interactions , 2008, Pharmaceutical Research.
[41] M. Niemi,et al. Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.
[42] Y. Sugiyama,et al. Ethnic Variability in the Plasma Exposures of OATP1B1 Substrates Such as HMG‐CoA Reductase Inhibitors: A Kinetic Consideration of Its Mechanism , 2013, Clinical pharmacology and therapeutics.
[43] Jian Lin,et al. Quantitative Prediction of Repaglinide-Rifampicin Complex Drug Interactions Using Dynamic and Static Mechanistic Models: Delineating Differential CYP3A4 Induction and OATP1B1 Inhibition Potential of Rifampicin , 2013, Drug Metabolism and Disposition.
[44] Diana Kazolias,et al. Use of Cryopreserved Human Hepatocytes in Sandwich Culture to Measure Hepatobiliary Transport , 2006, Drug Metabolism and Disposition.
[45] Bo Feng,et al. Quantitative prediction of renal transporter-mediated clinical drug-drug interactions. , 2013, Molecular pharmaceutics.
[46] M. Jamei,et al. A Mechanistic Framework for In Vitro–In Vivo Extrapolation of Liver Membrane Transporters: Prediction of Drug–Drug Interaction Between Rosuvastatin and Cyclosporine , 2013, Clinical Pharmacokinetics.
[47] Yi Wang,et al. Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin , 2008, Drug Metabolism and Disposition.
[48] Yuichi Sugiyama,et al. Transporters as a determinant of drug clearance and tissue distribution. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[49] Kazuya Maeda,et al. Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans , 2009, Journal of Pharmacology and Experimental Therapeutics.
[50] Malcolm Rowland,et al. Cyclosporine Inhibition of Hepatic and Intestinal CYP3A4, Uptake and Efflux Transporters: Application of PBPK Modeling in the Assessment of Drug-Drug Interaction Potential , 2012, Pharmaceutical Research.
[51] Y Kumagai,et al. Identification of the Rate‐Determining Process in the Hepatic Clearance of Atorvastatin in a Clinical Cassette Microdosing Study , 2011, Clinical pharmacology and therapeutics.
[52] K. Maeda,et al. Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes. , 2012, Molecular pharmaceutics.
[53] T. Andersson,et al. The Impact of Solute Carrier (SLC) Drug Uptake Transporter Loss in Human and Rat Cryopreserved Hepatocytes on Clearance Predictions , 2014, Drug Metabolism and Disposition.
[54] M. Niemi,et al. Impact of OATP transporters on pharmacokinetics , 2009, British journal of pharmacology.